Library Open Repository
Acorda Therapeutics: Rebuilding the Spinal Cord
Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic in-licensing choices, including what disease indication, what stage of development, how many molecules, and on what terms.
To allow students to examine a portfolio of choices and their impact on the overall business rather than on a single licensing decision.
New York, NY; United States; Biotechnology industry; start-up; 2003
|Item Type:||Report (Other)|
|Publisher:||Harvard Business School|
|Identification Number - DOI:||Case (Field) 9-604-014|
|Date Deposited:||02 Jan 2008 06:03|
|Last Modified:||16 Jul 2008 16:41|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|